Talk:5-HT3 antagonist

Cisapride
Cisapride has 5-HT3 antagonist properties (though its primary action is 5-HT4 agonism), should it be included? -- Samir 04:42, 17 May 2007 (UTC)
 * I thought of that, and renzapride as well, but left it in my sandbox; I couldn't figure out where to place it (at the bottom of the page, perhaps?) Fvasconcellos (t·c) 13:31, 17 May 2007 (UTC)
 * Noted in the "Available agents" section. I still need to cite it, and you're more than welcome to expand :) Fvasconcellos (t·c) 17:53, 20 May 2007 (UTC)

EPS with ondansetron?
(review) and. Warrants a closer look at the literature. Fvasconcellos (t·c) 14:15, 24 August 2007 (UTC)

Generics
A bunch of generic formulations of granisetron have received tentative FDA approval, and will probably reach the market this year. Something to keep an eye on. Fvasconcellos (t·c) 21:56, 23 September 2007 (UTC)

a few possibilities
I made a couple of minor changes to the article's structure here and there. The article might be getting close to GA, but needs a little more work, I think. The pharmacokinetics section is really too short, though nicely referenced. I think it could be expanded somehow.

I'm not real crazy with the 'available agents' list; I think it's still a little too "listy", though not nearly as bad as some GA nominees I've seen! I'd do away with the bold links of the drug names, as it jumps out at you too strongly. It seems like this could be converted into a 'history' section, which would sort of accomplish two things at once -- listing the various drugs of the class in an easy to see format as well as providing information on the history of development of this class. Dr. Cash 23:54, 26 September 2007 (UTC)
 * Thank you for your edits. I'm a big fan of definition lists, especially when the section is concise. I could simply change it into "History of available agents"; the list is already in chronological order. It wouldn't be a list anymore, and wouldn't quite be a timeline; I'm not sure this is a great idea—if the content is listy, you may as well make it into a proper list :) I'll reword in my sandbox and see how it can become more proselike. I thought of adding a small table of pharmacokinetic parameters to the PK section. Would that be too much? Fvasconcellos (t·c) 00:19, 27 September 2007 (UTC)

Other agents
We should chase down information on: There appear to be several others in development. This appears to be an interesting possible source. Fvasconcellos (t·c) 22:42, 1 November 2007 (UTC)
 * Azasetron
 * Bemesetron
 * Ramosetron

Why are there two mechanism of action subheadings?
Is there a reason a second mechanism of action is described at the end of the article? Would it be a good idea to merge it with the existing subheading, or delete it altogether? — Preceding unsigned comment added by 76.64.229.96 (talk) 19:47, 5 July 2014 (UTC)

Orphaned references in 5-HT3 antagonist
I check pages listed in Category:Pages with incorrect ref formatting to try to fix reference errors. One of the things I do is look for content for orphaned references in wikilinked articles. I have found content for some of 5-HT3 antagonist's orphans, the problem is that I found more than one version. I can't determine which (if any) is correct for this article, so I am asking for a sentient editor to look it over and copy the correct ref content into this article.

Reference named "": From Bromo-DragonFLY:  From Urapidil:  

I apologize if any of the above are effectively identical; I am just a simple computer program, so I can't determine whether minor differences are significant or not. AnomieBOT ⚡ 19:47, 30 November 2017 (UTC)